October 7, 2026 · 2 min read
Thymosin alpha-1: the thymic peptide and immune modulation research
A summary of reviews on thymosin alpha-1, a peptide first isolated from thymic tissue, and how it is reported to act on dendritic cells and T cells.
Thymosin alpha-1 (Ta1) is a 28-amino-acid peptide first isolated from thymic tissue. The thymus is where T cells mature, and Ta1 was identified as the compound that restored immune function in mice that had lost their thymus. A synthetic version has since been studied in clinical settings, and the reviews below summarize that work.
The thymosin alpha-1 sequence
Sequence: Serine, Aspartic acid, Alanine, Alanine, Valine, Aspartic acid, Threonine, Serine, Serine, Glutamic acid, Isoleucine, Threonine, Threonine, Lysine, Aspartic acid, Leucine, Lysine, Glutamic acid, Lysine, Lysine, Glutamic acid, Valine, Valine, Glutamic acid, Glutamic acid, Alanine, Glutamic acid, Asparagine.
- Polar
- Negatively charged
- Hydrophobic
- Positively charged
- Length
- 28 amino acids
- Average mass
- 3,108.3 Da
- Formula
- C129H215N33O55
Proposed mechanism
A 2016 review in Vitamins and Hormones describes Ta1 as pleiotropic, meaning it affects several immune cell subsets. It reports that Ta1 signals through Toll-like receptors on myeloid and plasmacytoid dendritic cells, which activates signaling pathways and cytokine production. From that, the authors expected it to be useful wherever immune suppression is the problem, whether from aging, infection or cancer.
How Ta1 is thought to act
- 1
Toll-like receptors
Ta1 signals through them on myeloid and plasmacytoid dendritic cells.
- 2
Signaling
Pathways are activated.
- 3
Cytokines
Immune-related cytokines are produced.
- 4
Immune cell subsets
Several subsets are affected.
Where it has been studied
A 2020 review in the World Journal of Virology lists the main directions: immunocompromised states and malignancies, boosting vaccine response, and lowering morbidity and mortality in sepsis and other infections. It also raises the hypothesis that Ta1 might help severely ill COVID-19 patients by rebalancing T cell activation. The authors say the antiviral properties deserve more investigation, which is not the same as saying the question is answered.
- Cancer: a 2023 review looks at how Ta1 may affect tumor immunity and combine with other therapies.
- Aging: a 2025 review connects thymic involution, immune aging and Ta1.
- Infection and sepsis: clinical studies of mixed size and quality, so systematic reviews matter here.
Four directions of research
Immunocompromised states and cancer
Studied in people with weakened immunity and malignancies.
Vaccine response
Studied as a way to enhance vaccine response.
Sepsis and infection
Studied for effects on morbidity and mortality.
COVID-19
A hypothesis about rebalancing T cell activation, flagged for more research.
Reading the studies
Immune modulation is a broad claim. A peptide can move one measure, say a cell count, without changing an outcome a patient would notice. When you read a Ta1 paper, check whether the endpoint was a lab marker or a clinical outcome, and whether the trial was randomized and controlled. The reviews themselves mostly call for larger, better-designed trials.
References
- King R, Tuthill C. Immune Modulation with Thymosin Alpha 1 Treatment. Vitam Horm 2016.
- Dominari A et al. Thymosin alpha 1: A comprehensive review of the literature. World J Virol 2020.
- Wei Y et al. Thymosin alpha-1 in cancer therapy: Immunoregulation and potential applications. Int Immunopharmacol 2023.
- Simonova MA et al. Aging and Thymosin Alpha-1. Int J Mol Sci 2025.